BSXBoston Scientific

1. Oct 7, 2026Chief Operating Officer On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of …Director or officer change · Form 8-K
2. Sep 23, 2026On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.Director or officer change · Form 8-K
3. Sep 8, 2026As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “Company”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global …Material cybersecurity incident · Form 8-K
4. Aug 26, 2026On August 25, 2026, Boston Scientific Corporation (the “Company”) identified a cybersecurity incident affecting certain of its information technology systems that has resulted in a global disruption to the Company’s operations.Other event · Form 8-K
5. Jul 27, 2026On July 21, 2026, the Board of Directors of Boston Scientific Corporation (the “Company”) approved a new global restructuring program (the “2026 Restructuring Plan”)Exit or disposal costs (restructuring) · Form 8-K
6. May 18, 2026Accelerated Share Repurchase Program On May 18, 2026, Boston Scientific Corporation (the “Company”) issued a press release announcing that the Company has entered into an accelerated share repurchase (“ASR”) agreement with JPMorgan Chase Bank, National Association for $2 billion (the “Repurchase Price”) of its common …Other event · Form 8-K
7. May 18, 2026Investment Agreement with MiRus LLC On May 18, 2026, Boston Scientific Corporation (the “Company”) issued a press release announcing that the Company has entered into an investment agreement (the “Investment Agreement”) with MiRus LLC (“MiRus”), a privately held company developing and commercializing proprietary novel …Other event · Form 8-K
8. May 5, 2026On April 30, 2026, the stockholders of Boston Scientific Corporation (the “Company”), at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), approved amendments (the “Charter Amendments”) to the Company’s Third Restated Certificate of Incorporation, as described in the Company’s definitive proxy …Charter/bylaw amendment or fiscal-year change · Form 8-K
9. Mar 30, 2026On March 28, 2026, Boston Scientific Corporation (the “Company”) issued a press release announcing results from the Company's HI-PEITHO clinical trial.Other event · Form 8-K
10. Feb 26, 2026Revolving Credit Agreement On February 26, 2026, Boston Scientific Corporation (the “Company”) entered into a $3.000 billion revolving credit agreement (the “2026 Revolving Credit Agreement”) by and among the Company, as borrower, the several lenders party thereto, and Wells Fargo Bank, National Association, as …Material agreement entered · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.